Clinical trialsCompany release

Nkarta presents first NKX019 CAR NK data in systemic sclerosis and myositis

🇺🇸 Nkarta, Inc. (NKTX) · Mon 09 Nov 2026

Initial Phase 1/2 results for the allogeneic CD19-targeted CAR NK therapy support a compressed Day 0/2/4 dosing schedule, and the company plans FDA talks on a registrational path.

Nkarta presented its first clinical data for NKX019, an allogeneic CD19-targeted CAR NK cell therapy, in systemic sclerosis and idiopathic inflammatory myopathy. The results were shared at ACR Convergence on 9 November 2026, with a data cut-off of 18 September 2026.

The company reported that exposure to NKX019 increased with dose. It also said that the recovery of host T cells began before the Day 7 dose was given.

Nkarta says these observations support moving to a compressed schedule, with doses on Days 0, 2 and 4. The summary provided does not give patient numbers, response rates or safety findings, so the strength of the early signal cannot be judged from it.

Nkarta also plans interactions with the US Food and Drug Administration on a registrational path and on dose selection. No timelines or details of the proposed development plan were given.

What it means for your team

  • The data are early Phase 1/2 results in autoimmune disease; efficacy and safety details were not included in the material available, so they should be checked against the full presentation.
  • A compressed Day 0/2/4 schedule, if adopted, would change the dosing and logistics assumptions for allogeneic cell therapy in these indications.
  • Planned FDA discussions on a registrational path and dose selection are the next regulatory milestone to watch for NKX019.
  • Teams tracking cell therapies in autoimmune disease may see this as another sign that CD19-directed approaches are being developed beyond oncology.

Company's press release (SEC filing): Nkarta, Inc. ↗

Article written by VigiEye from the official source (Nkarta, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Clinical trials All →